All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
On September 6, 2022, it was announced that brexucabtagene autoleucel (brexu-cel) received European marketing authorization from the European Commission for the treatment of patients aged ≥26 years with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL).1
Given the high relapse rate, low survival rate, and high treatment burden in adult patients with B-ALL, this meaningful clinical development will be beneficial in addressing an unmet need in this population.
Your opinion matters
Brexucabtagene autoleucel receives a positive opinion from EMA CHMP for the treatment of patients with R/R B-ALL
Given the high treatment burden and low-survival rate of patients with R/R B-ALL, approval of brexu-cel marks a positive treatment...
Two-year follow-up of KTE-X19 in adult patients with R/R B-ALL: ZUMA-3 trial
The updated findings from the ZUMA-3 trial demonstrate that with longer follow-up and a larger pooled data set, outcomes remained stable over time in adult patients with R/R...
Subscribe to get the best content related to ALL delivered to your inbox